Sientra (NASDAQ:SIEN) Research coverage began at Lake Street Capital
Lake Street Capital began covering the shares of His (NASDAQ: HIS – Get a rating) in a research note published Thursday morning, Market assessments reports. The company issued a buy rating and a target price of $8.00 on the shares of the medical device supplier.
A number of other research analysts have also weighed in on HIS recently. Colliers Securities restated a buy rating on Sientra shares in a Tuesday, March 22 research report. Stifel Nicolaus lowered his price target on Sientra shares from $11.00 to $7.00 and set a buy rating on the stock in a Thursday, March 24 research report. UBS Group lowered its price target on Sientra shares from $10.00 to $8.00 and set a buy rating on the stock in a Tuesday, March 29 research report. Canaccord Genuity Group lowered its price target on Sientra shares from $10.00 to $8.00 and set a buy rating on the stock in a research report Tuesday, March 29. To finish, Zacks Investment Research downgraded Sientra shares from a hold rating to a sell rating in a Tuesday, March 29 research report. One analyst rated the stock with a sell rating, one issued a hold rating and seven assigned the company’s stock a buy rating. According to MarketBeat, the company currently has a buy consensus rating and an average target price of $7.75.
NASDAQ: HIS opened at $1.99 on Thursday. The company’s 50-day moving average price is $2.53 and its 200-day moving average price is $3.71. Sientra has a 52 week minimum of $1.98 and a 52 week maximum of $9.14. The company has a current ratio of 1.76, a quick ratio of 1.10 and a debt ratio of 1.53.
His (NASDAQ: HIS – Get a rating) last released its quarterly results on Wednesday, March 23. The medical device supplier reported ($0.27) EPS for the quarter, missing the Zacks consensus estimate of ($0.19) by ($0.08). Sientra had a negative net margin of 112.89% and a negative return on equity of 865.36%. The company posted revenue of $22.65 million for the quarter, compared to $22.50 million expected by analysts. In the same quarter of the previous year, the company achieved EPS of ($0.38). Sell-side analysts expect Sientra to post YTD EPS of -0.84.
A number of institutional investors and hedge funds have recently increased or reduced their stakes in the company. BlackRock Inc. increased its position in Sientra shares by 1.8% during the fourth quarter. BlackRock Inc. now owns 3,693,642 shares of the medical device supplier valued at $13,556,000 after purchasing an additional 66,003 shares during the period. Morgan Stanley increased its position in Sientra shares by 11.2% during the third quarter. Morgan Stanley now owns 3,117,077 shares of the medical device supplier valued at $17,861,000 after purchasing an additional 314,815 shares during the period. Senvest Management LLC increased its position in Sientra shares by 8.1% during the fourth quarter. Senvest Management LLC now owns 2,861,039 shares of the medical device supplier valued at $10,500,000 after purchasing an additional 215,000 shares during the period. Schroder Investment Management Group increased its position in Sientra shares by 3.0% during the fourth quarter. Schroder Investment Management Group now owns 2,837,877 shares of the medical device supplier valued at $10,415,000 after purchasing an additional 81,659 shares during the period. Finally, Bamco Inc. NY increased its position in Sientra shares by 9.0% during the third quarter. Bamco Inc. NY now owns 2,578,364 shares of the medical device supplier valued at $14,774,000 after purchasing an additional 213,001 shares during the period. Institutional investors and hedge funds hold 89.48% of the company’s shares.
About Sientra (Get a rating)
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan and BIOCORNEUM brands.
Get news and reviews for Sientra Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Sientra and related companies with MarketBeat.com’s FREE daily newsletter.
Comments are closed.